Journal ArticleOPEN ACCESS

Olaparib

British Journal of Clinical Pharmacology (2016) 81(1) 171-173
DOI: 10.1111/bcp.12761
30Citations
Citations of this article
117Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. This results in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination.

Cite

CITATION STYLE

APA

Goulooze, S. C., Cohen, A. F., & Rissmann, R. (2016). Olaparib. British Journal of Clinical Pharmacology, 81(1), 171–173. https://doi.org/10.1111/bcp.12761

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free